No Data
No Data
Anhui Fengyuan Pharmaceutical (000153.SZ): The proportion of overseas revenue for the year 2024 is less than 2%.
On April 25, Gelonghui reported that Anhui Fengyuan Pharmaceutical (000153.SZ) stated in a recent investor relations activity that the overseas revenue proportion for 2024 is less than 2%, with the main business market in Southeast Asia.
Fengyuan Pharmaceutical: First Quarter Report 2025
Anhui Fengyuan Pharmaceutical (000153.SZ): In the first quarter, net income was 38.02 million yuan, a year-on-year decrease of 19.12%.
Gelonghui reported on April 24 that Anhui Fengyuan Pharmaceutical (000153.SZ) announced its first quarter report, with revenue of 0.94 billion yuan, a year-on-year decrease of 16.05%. The net income attributable to the shareholders of the listed company was 38.02 million yuan, a year-on-year decrease of 19.12%. The net income attributable to the shareholders of the listed company, excluding non-recurring gains and losses, was 33.527 million yuan, a year-on-year decrease of 19.55%.
Fengyuan Pharmaceutical: 2024 Annual Report
Fengyuan Pharmaceutical: 2024 Annual Report Summary
Express News | Anhui Fengyuan Pharmaceutical: The net income for 2024 is 0.161 billion yuan, a year-on-year increase of 0.97%.